MapLight Therapeutics, Inc. Payments of Financing Costs
MapLight Therapeutics, Inc. (MPLT) reported Payments of Financing Costs of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2026-08-13
- MapLight Therapeutics, Inc. payments of financing costs for the quarter ending 2025-12-31 was $3.89M, a 22805.88% increase year-over-year.
- MapLight Therapeutics, Inc. payments of financing costs for the quarter ending 2025-09-30 was $916.00K.
- MapLight Therapeutics, Inc. payments of financing costs for the quarter ending 2025-06-30 was $159.00K.
- MapLight Therapeutics, Inc. payments of financing costs for the quarter ending 2025-03-31 was $52.00K.
- MapLight Therapeutics, Inc. payments of financing costs for fiscal 2025 was $5.02M, a 129.27% increase from fiscal 2024.
- MapLight Therapeutics, Inc. payments of financing costs for fiscal 2024 was $2.19M.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $3.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $4.81M derived: sum of 2 quarters · filed 2026-03-26 | $4.97M derived: sum of 3 quarters · filed 2026-08-13 | $5.02M 10-K · filed 2026-03-26 |
| 2025-09-30 | $916.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-12-04 | $1.07M derived: sum of 2 quarters · filed 2026-08-13 | $1.13M 10-Q · filed 2025-12-04 | $1.14M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $159.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $211.00K 10-Q · filed 2026-08-13 | $228.00K derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-03-31 | $52.00K 10-Q · filed 2026-05-14 | $69.00K derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.19M 10-K · filed 2026-03-26 | ||
| 2024-09-30 | $2.17M 10-Q · filed 2025-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |